Melanoma Biomarker Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00348088|
Recruitment Status : Completed
First Posted : July 4, 2006
Last Update Posted : December 13, 2012
|Condition or disease|
Malignant Melanoma has rapidly increased in incidence over the past thirty years, at a rate of roughly 3% per year. In 2005, approximately 59,000 new cases of melanoma were diagnosed with 8000 deaths. While the majority of early melanomas can be surgically cured, advanced melanoma has an extremely poor prognosis. Current chemotherapy and immunotherapy options for advanced melanoma still offer response rates of only 10-20%. Thus, the elucidation of biomarkers in melanoma, both diagnostic and prognostic, is an important area for investigation.
CXCL1 is a chemokine whose expression is upregulated in melanoma. We postulate that CXCL1 plays an important role in the progression of melanoma to invasive disease. Our hypothesis states that serum CXCL1 levels correlate with the presence of melanoma.
- To measure serum levels of CXCL1 in untreated, metastatic melanoma patients and to compare to serum CXCL1 levels in normal controls.
- To measure and compare centrally and peripherally collected serum CXCL1 levels in untreated, metastatic melanoma.
Blood will be collected from metastatic melanoma patients on one occasion, both peripherally and centrally. Control will have blood collected peripherally on one occasion. The blood will be processed and then tested in a blinded, batched fashion.
|Study Type :||Observational|
|Actual Enrollment :||20 participants|
|Official Title:||CXCL1 Biomarker Study in Metastatic Melanoma|
|Study Start Date :||May 2006|
|Actual Primary Completion Date :||September 2011|
|Actual Study Completion Date :||September 2011|
- Observational study only [ Time Frame: May 2006-September 2011 ]To determine, via sandwiched ELISA, the presence and level of CXCL1 in the serum of patients with metastatic melanoma and to compare these values with CXCL1 levels in normal controls.
- Observational study only [ Time Frame: May 2006-September 2011 ]To compare serum CXCL1 levels collected peripherally and centrally, in metastatic melanoma patients and To collect serum samples for future study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00348088
|United States, Maryland|
|Johns Hopkins University - Sidney Kimmel Comprehensive Cancer Center|
|Baltimore, Maryland, United States, 21231|
|Principal Investigator:||William H Sharfman, MD||Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center|